BLOG/πŸ‡ΊπŸ‡ΈUnited StatesΒ·Β·daily

US Merger & Acquisition SEC Filings β€” February 23, 2026

USA M&A & Takeover Activity

16 high priority16 total filings analysed

Executive Summary

A surge of 16 M&A-related 8-K filings on February 24, 2026, signals heightened takeover and acquisition activity in the US market, dominated by SPACs (10+ filings) announcing material definitive agreements (Item 1.01) and equity issuances (Item 3.02), alongside notable operating company deals in energy and healthcare. Common themes include acquisition completions (Item 2.01 in 5 filings), financial obligations (Item 2.03 in 2), and governance changes, but pervasive lack of disclosed quantitative metrics, deal valuations, parties, synergies, or period-over-period trends limits precise assessment, with overall neutral sentiment across 15/16 filings. High materiality (8-9/10) in 8 filings underscores potential portfolio impact, particularly SPAC de-SPAC processes and strategic acquisitions in oil/gas (Northern Oil) and biotech/fertility (Protagenic, INVO, Cardiff). No enriched period comparisons available, but pattern of completions vs announcements suggests accelerating deal closures amid neutral risk levels. Investors should monitor for follow-on disclosures on dilution risks from unregistered sales and integration outcomes, as SPAC-heavy activity points to a potential M&A rebound.

Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from February 22, 2026.

Investment Signals(10)

  • Completion of acquisition (Item 2.01) alongside material agreement provides scale in oil & gas sector, high materiality 9/10

  • New material definitive agreement (Item 1.01) post-termination of prior deal signals resilient M&A pipeline, mixed sentiment with strategic asset potential

  • β–²

    Acquisition completion (Item 2.01) with governance updates (Item 5.03) indicates strategic expansion in fertility tech, materiality 8/10

  • β–²

    Asset acquisition completion (Item 2.01) in biotech space enhances portfolio, high materiality 8/10

  • Material agreement entry (Item 1.01) typical for SPAC de-SPAC value creation, materiality 8/10

  • Material agreement (Item 1.01) advances space sector merger potential, materiality 8/10

  • Comprehensive M&A filing with agreement (Item 1.01) and governance changes positions for de-SPAC upside, materiality 8/10

  • Material definitive agreement (Item 1.01) flags early-stage takeover opportunity, materiality 8/10

  • Merger/acquisition Regulation FD disclosure (Item 7.01) hints at positive updates, despite neutral sentiment

  • Shareholder vote submission (Item 5.07) nears SPAC merger approval milestone

Risk Flags(9)

Opportunities(8)

Sector Themes(6)

  • SPAC Merger Surge
    β—†

    10/16 filings from SPACs (RF III x2, Pelican, EQV, Horizon, Cohen, Trailblazer, PALOMA, Art Tech x2, SPACSphere) with Item 1.01/8.01, neutral sentiment but high materiality avg 6/10 signals de-SPAC wave, watch dilution from Item 3.02

  • Energy M&A Momentum
    β—†

    Northern Oil & Gas acquisition completion (Item 2.01/2.03) stands out as sole energy play, materiality 9/10 implies sector consolidation amid leverage add

  • Healthcare/Biotech Activity
    β—†

    3 filings (Protagenic termination+new deal, INVO fertility acquisition, Cardiff Oncology completion) with mixed/neutral sentiment, avg materiality 8/10 highlights strategic asset grabs despite disclosure gaps

  • Dilution via Equity Sales
    β—†

    Item 3.02 in 6 filings (Protagenic, EQV, INVO, Horizon, PALOMA) common in SPACs, risks NAV erosion but funds deals

  • Governance Shifts in Deals
    β—†

    Item 5.02/5.03 in INVO, PALOMA, Art Tech suggest M&A-driven board refreshes for post-merger stability

  • Disclosure Opacity Trend
    β—†

    16/16 lack quantitative metrics/valuations, elevating uncertainty but creating alpha for early diligence on exhibits

Watch List(8)

Filing Analyses(16)
RF Acquisition Corp III8-Kneutralmateriality 3/10

24-02-2026

RF Acquisition Corp III filed an 8-K on February 24, 2026 (AccNo: 0001829126-26-001581), disclosing unregistered sales of equity securities under Item 3.02, other events under Item 8.01, and financial statements and exhibits under Item 9.01. No specific details on deal structure, parties involved, valuation, synergies, regulatory pathway, shareholder impact, or market implications are provided. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.

NORTHERN OIL & GAS, INC.8-Kneutralmateriality 9/10

24-02-2026

Northern Oil & Gas, Inc. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), alongside creation of a direct financial obligation (Item 2.03) and Regulation FD disclosure (Item 7.01). No quantitative metrics, deal values, parties involved, synergies, or financial impacts are disclosed in the provided filing information. Item 9.01 references financial statements and exhibits, but specifics are NOT_DISCLOSED.

  • Β·AccNo: 0001193125-26-064523
  • Β·Filing Size: 338 KB
  • Β·Event Type: Merger/Acquisition
Pelican Acquisition Corp8-Kneutralmateriality 3/10

24-02-2026

Pelican Acquisition Corp filed an 8-K on February 24, 2026 (AccNo: 0001829126-26-001595), disclosing information under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits related to a merger/acquisition event. No specific details on deal structure, parties, valuation, financial terms, or strategic rationale are explicitly stated in the provided filing summary. All quantitative metrics, named entities beyond the filer, and scheduled events are NOT_DISCLOSED.

Protagenic Therapeutics, Inc.new8-Kmixedmateriality 8/10

24-02-2026

Protagenic Therapeutics, Inc. filed an 8-K on February 24, 2026, disclosing entry into a material definitive agreement (Item 1.01) and termination of a prior material definitive agreement (Item 1.02), alongside completion of an acquisition or disposition of assets (Item 2.01) and unregistered sales of equity securities (Item 3.02). Other events are noted under Item 8.01, with financial statements and exhibits provided under Item 9.01. No quantitative financial metrics, deal values, or specific parties are disclosed.

EQV Ventures Acquisition Corp.8-Kneutralmateriality 8/10

24-02-2026

EQV Ventures Acquisition Corp. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger/acquisition, along with unregistered sales of equity securities (Item 3.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific transaction parties, deal size, valuation, or financial metrics are disclosed in the provided filing summary. This appears to be a standard SPAC business combination announcement without detailed terms.

INVO Fertility, Inc.8-Kneutralmateriality 8/10

24-02-2026

INVO Fertility, Inc. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), alongside unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws and change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements/exhibits (Item 9.01). This filing signals a completed merger/acquisition transaction, but no specific parties, terms, values, or impacts are disclosed. No quantitative metrics, positive or negative changes, or performance variations are provided.

Horizon Space Acquisition II Corp.8-Kneutralmateriality 8/10

24-02-2026

Horizon Space Acquisition II Corp. filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement under Item 1.01, creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, and unregistered sales of equity securities under Item 3.02. Item 8.01 reports other events, with financial statements and exhibits under Item 9.01. No specific deal terms, financial metrics, parties involved, or performance comparisons are disclosed.

  • Β·AccNo: 0001929980-26-000053
  • Β·Filing size: 240 KB
Cohen Circle Acquisition Corp. II8-Kneutralmateriality 3/10

24-02-2026

Cohen Circle Acquisition Corp. II filed an 8-K on February 24, 2026 (AccNo: 0001213900-26-019871, Size: 288 KB), disclosing other events under Item 8.01 and financial statements and exhibits under Item 9.01, in connection with a merger/acquisition event. No specific details on deal structure, parties involved, valuation, terms, financial metrics, synergies, regulatory pathway, or shareholder impacts were explicitly stated. Sector not specified, and no quantitative data, comparisons, or scheduled events provided.

RF Acquisition Corp III8-Kneutralmateriality 3/10

24-02-2026

RF Acquisition Corp III filed an 8-K on February 24, 2026 (AccNo: 0001829126-26-001610, Size: 265 KB) disclosing other events under Item 8.01 and financial statements and exhibits under Item 9.01 in connection with a merger/acquisition event. No specific details on parties, deal structure, valuation, terms, financial metrics, or performance comparisons are disclosed in the filing summary provided. No positive or negative metrics, changes, or scheduled events are mentioned.

  • Β·AccNo: 0001829126-26-001610
Trailblazer Merger Corp I8-Kneutralmateriality 5/10

24-02-2026

Trailblazer Merger Corp I filed an 8-K on 2026-02-24 (AccNo: 0001213900-26-019945, Size: 334 KB) disclosing Item 5.07 regarding Submission of Matters to a Vote of Security Holders in connection with a Merger/Acquisition event. No specific details on vote results, parties involved, deal structure, financial terms, or metrics are provided. Sector is not specified.

Cardiff Oncology, Inc.8-Kneutralmateriality 8/10

24-02-2026

Cardiff Oncology, Inc. filed an 8-K on 2026-02-24 announcing the completion of an acquisition or disposition of assets under Item 2.01. The filing includes financial statements and exhibits under Item 9.01. No quantitative metrics, deal details, or performance comparisons are disclosed.

Art Technology Acquisition Corp.8-Kneutralmateriality 2/10

24-02-2026

Art Technology Acquisition Corp. filed an 8-K on 2026-02-24 under Item 5.02 disclosing matters related to departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific names, dates, financial details, transaction information, or quantitative metrics are mentioned in the filing summary. No positive or negative performance indicators, scheduled events, or M&A details are provided.

PALOMA ACQUISITION CORP I8-Kneutralmateriality 8/10

24-02-2026

PALOMA ACQUISITION CORP I filed an 8-K on 2026-02-24 disclosing entry into a material definitive agreement under Item 1.01, likely related to a merger/acquisition. The filing also covers unregistered sales of equity securities (Item 3.02), departures/elections/appointments of directors/officers and compensatory arrangements (Item 5.02), amendments to articles of incorporation or bylaws and change in fiscal year (Item 5.03), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No specific details on parties, structure, valuation, terms, or metrics are disclosed.

Art Technology Acquisition Corp.8-Kneutralmateriality 5/10

24-02-2026

Art Technology Acquisition Corp. filed an 8-K on 2026-02-24 under Item 8.01 (Other Events) announcing a merger/acquisition-related event. Item 9.01 discloses financial statements and exhibits. No specific deal structure, parties, valuation, or financial metrics are detailed in the filing summary provided.

  • Β·Filing Accession Number: 0001213900-26-019947
  • Β·File size: 259 KB
  • Β·Sector: NOT_DISCLOSED
SPACSphere Acquisition Corp.8-Kneutralmateriality 6/10

24-02-2026

SPACSphere Acquisition Corp. filed an 8-K on 2026-02-24 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), announcing events related to a merger/acquisition. No specific deal terms, parties, valuations, financial metrics, synergies, regulatory pathways, or shareholder impacts were disclosed. No quantitative data, period-over-period comparisons, or scheduled events were mentioned.

Unknown8-Kneutralmateriality 8/10

24-02-2026

The filer submitted an 8-K on 2026-02-24 (AccNo: 0001477932-26-001011, 289 KB) disclosing under Item 1.01 entry into a Material Definitive Agreement related to a Merger/Acquisition event, with Item 9.01 covering Financial Statements and Exhibits. No specific deal structure, parties, valuation, terms, financial metrics, or other quantitative details are provided in the filing summary. This is purely informational without positive or negative performance indicators.

Get daily alerts with 10 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 16 filings

πŸ‡ΊπŸ‡Έ More from United States

View all β†’
US Merger & Acquisition SEC Filings β€” February 23, 2026 | Gunpowder Blog